Skip to main content
HeartCited

健康状况

18 基于循证研究的健康状况与补充剂信息

Explore health conditions with evidence-graded supplement recommendations. Each condition page ranks ingredients by the strength of clinical research supporting them.

How We Grade Evidence

每个健康状况页面按临床证据强度对补充剂成分进行排序。以下是各等级的含义:

A

Strong Evidence

Multiple randomized controlled trials (RCTs) or meta-analyses with consistent positive results and large sample sizes.

B

Good Evidence

At least one RCT with mostly consistent results across studies. Evidence suggests benefit but more research may be needed.

C

Some Evidence

Small studies or observational data with some positive signals. Promising but insufficient for strong recommendations.

D

Very Early Research

In vitro studies, case reports, or pilot studies only. Early-stage research that requires clinical validation.

High Blood Pressure (Hypertension)

47% of US adults (116 million); ~1.28 billion adults worldwide

Often asymptomatic ('silent killer') Severe: headache, shortness of breath, nosebleeds Chest pain +2

High Cholesterol (Hyperlipidemia)

38% of US adults have total cholesterol >=200 mg/dL; 12% have LDL >=160 mg/dL

Usually asymptomatic Xanthomas (tendon/skin deposits) in severe cases Corneal arcus +1

Atherosclerosis

Subclinical atherosclerosis present in >50% of adults over 40

Often asymptomatic until advanced Angina Claudication +1

Heart Failure

6.7 million US adults; prevalence increases with age (10% in adults >65)

Dyspnea (exertional and at rest) Orthopnea Paroxysmal nocturnal dyspnea +3

Cardiac Arrhythmia

Atrial fibrillation: 33.5 million worldwide; PVCs: present in 75% of healthy adults

Palpitations Skipped beats Racing heart +3

Peripheral Artery Disease (PAD)

8.5 million US adults; 12-20% of adults >60 years

Intermittent claudication (leg pain with walking) Numbness/weakness in legs Cold legs/feet +2

Coronary Artery Disease (CAD)

20.5 million US adults; leading cause of death globally (17.9 million deaths/year)

Angina pectoris (chest pain/pressure with exertion) Shortness of breath Fatigue +1

Endothelial Dysfunction

Present in virtually all patients with cardiovascular risk factors

Usually asymptomatic (subclinical) Reduced exercise tolerance Erectile dysfunction +1

Oxidative Stress (Cardiovascular)

Measurable biomarkers elevated in >80% of CVD patients

Subclinical; contributes to accelerated cardiovascular aging Associated with endothelial dysfunction Arterial stiffness +1

Cardiovascular Inflammation

hs-CRP >2 mg/L present in ~25% of US adults

Usually measured by lab markers (hs-CRP, IL-6, TNF-alpha) Associated with accelerated atherosclerosis Plaque instability

High Triglycerides (Hypertriglyceridemia)

25-30% of US adults have elevated triglycerides (>=150 mg/dL)

Usually asymptomatic Very high levels (>500): eruptive xanthomas Lipemia retinalis +1

Elevated Homocysteine (Hyperhomocysteinemia)

5-10% of general population; up to 30-40% of elderly

Usually asymptomatic Associated with premature atherosclerosis Thromboembolism

Arterial Stiffness

Universal with aging; 20-30% of adults >60 have PWV >10 m/s

Usually asymptomatic Contributes to isolated systolic hypertension Widened pulse pressure +1

Heart Palpitations

Very common — up to 16% of primary care visits cite palpitations

Awareness of heartbeat Fluttering or pounding sensation Skipping beats +3

Varicose Veins (Chronic Venous Insufficiency)

20-30% of adults; higher in women (2:1 ratio)

Visible dilated veins Leg heaviness/aching Swelling (worse with standing) +3

Poor Blood Circulation

Symptoms of poor circulation affect 15-20% of adults >50

Cold hands/feet Numbness/tingling in extremities Slow wound healing +3

Post-Heart Attack Recovery (Post-MI)

~805,000 MIs/year in the US; 200,000 are recurrent events

Fatigue Reduced exercise tolerance Chest discomfort +2

Metabolic Syndrome (Cardiovascular Aspects)

34% of US adults; prevalence increasing globally parallel to obesity epidemic

Central obesity (waist >40 inches men, >35 inches women) Elevated fasting glucose (>100 mg/dL) Elevated triglycerides (>150 mg/dL) +2

FDA 免责声明: 这些声明未经美国食品药品监督管理局(FDA)评估。本网站上的产品和信息无意用于诊断、治疗、治愈或预防任何疾病。所展示的证据等级基于我们对已发表的同行评审研究的分析,不构成医疗建议。在开始任何补充剂方案之前,请务必咨询您的医疗保健提供者。